Tibsovo
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Boston, Massachusetts, 02210, United Sta...Website
www.tibsovo.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Tibsovo
TIBSOVO is a prescription medicine designed for the treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and cholangiocarcinoma (CCA) in adults with an IDH1 mutation. The product specifically targets patients with newly diagnosed AML who are 75 years or older or have health problems preventing chemotherapy, as well as those whose conditions have recurred or not improved after previous treatments. The company emphasizes safety, providing comprehensive patient support services to educate about potential side effects and necessary monitoring during treatment. TIBSOVO is indicated for patients who have previously received treatment and requires healthcare provider testing to determine suitability.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tibsovo your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if Tibsovo had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Tibsovo launches new products
Earning: See what the market has to say on Tibsovo recently announced quarterly report
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Tibsovo has new funding data
Tibsovo, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Tibsovo
Check out if Tibsovo is spiking on competitors!
Check if Tibsovo has recently received funding, and reach out quickly before it becomes old news!
Recommended Actions
Find VP level buyers at Tibsovo
Find more new buyers
Compare Similar Companies to Tibsovo
Compare insights from companies similar to Tibsovo, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Tibsovo
<$5M
11-50
Private
-
-
N/A
Company Profile Activity
Activity Insights
Tibsovo is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Tibsovo is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Tibsovo.
Tibsovo Tech Stack
A closer look at the technologies used by Tibsovo
Tibsovo News & Media
Servier Announces FDA Filing Acceptance and Priority Review for TIBSOVO® (ivosidenib tablets) in the Treatment of IDH1-mutated Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS)
If approved, TIBSOVO will be the first and only approved targeted therapy for MDS patients with a susceptible IDH1 mutation Submission supported by comprehensive clinical data package, including updated results that demonstrate durable remissions and an acceptable safety profile BOSTON,...Servier Presents Updated Results for TIBSOVO® (ivosidenib tablets) in IDH1-mutated Relapsed/Refractory Myelodysplastic Syndromes at the 2023 European Hematology Association (EHA) Congress
Treatment with TIBSOVO resulted in durable remissions, including complete response in nearly 40% of patients, and an acceptable safety profile Servier plans to submit a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA) BOSTON, June 9, 2023...Servier Bolsters Position as the Leader in Mutant IDH Inhibition with Positive New IDH1-Mutated Acute Myeloid Leukemia Data at ASCO
Updated data from Phase 3 AGILE study show additional extension in median overall survival to 29.3 months with TIBSOVO® (ivosidenib tablets) in combination with azacitidine and confirm continued benefit of TIBSOVO as first-line treatment of newly-diagnosed acute myeloid leukemia (AML)...Servier receives European Commission approval of Tibsovo® (ivosidenib tablets) in IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma
Marketing Authorization granted for Tibsovo® as the first and only approved IDH1 targeted therapy in Europe IDH1-mutated Acute Myeloid Leukemia and IDH1-mutated Cholangiocarcinoma, difficult and hard-to-treat cancer PARIS and BOSTON, May 10, 2023 /PRNewswire/ -- Servier, a global...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tibsovo
Sign Up For FreeTo access detailed company insights
TIBSOVO is a prescription medicine designed for the treatment of acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and cholangiocarcinoma (CCA) in adults with an IDH1 mutation. The product specifically targets patients with newly diagnosed AML who are 75 years or older or have health problems preventing chemotherapy, as well as those w... Read More
